Coretech 5 (XPAR:MLCOT) Debt-to-Asset : 0.23 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Coretech 5 Debt-to-Asset?

Coretech 5's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €0.00 Mil. Coretech 5's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €0.02 Mil. Coretech 5's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was €0.11 Mil. Coretech 5's debt to asset for the quarter that ended in Dec. 2022 was 0.23.

Coretech 5 Debt-to-Asset Historical Data

The historical data trend for Coretech 5's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coretech 5 Debt-to-Asset Chart

Coretech 5 Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

14.92

5.20

8.57

12.15

0.23

Coretech 5 Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
Debt-to-Asset	Get a 7-Day Free Trial				14.92	5.20	8.57	12.15	0.23

Competitive Comparison of Coretech 5's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Coretech 5's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coretech 5's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Coretech 5's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Coretech 5's Debt-to-Asset falls into.

Coretech 5 Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Coretech 5's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.024)	/	0.105
	=	0.23

Coretech 5's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.024)	/	0.105
	=	0.23

Coretech 5 (XPAR:MLCOT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Coretech 5 Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Coretech 5's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Coretech 5 (XPAR:MLCOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Coretech 5 (XPAR:MLCOT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 rue de Castiglione, Paris, FRA, 75 001

Website

https://www.coretech5.com

Coretech 5 Formerly Gour Medical AG is a pharmaceutical company. It develops and markets veterinary medicines and specialist pet. Its products include food supplements or nutraceuticals or related medical devices. The products are dedicated to the treatment of pain, allergies, behavioral disorders and improvement of quality of life. It sells its product under the brand Weedley.

Coretech 5 (XPAR:MLCOT) Headlines

No Headlines